Futura Medical Share Discussion Threads

[j777j] 13/9/2022 08:08

Manufacturing – Futura has also secured manufacturing capabilities of MED3000 with a FDA, EMA and UK approved manufacturer. The supply chain is now ready for commercial production, with capacity for initial launch supplies of MED3000.



MED3000 has an approved shelf-life of at least 3 years at point of sale.




Excellent news 3 year shelf life!!!! Bravo FUM



They have clearly learned and adapted



Will be worth £££££'s

[haveapunt1] 13/9/2022 08:07

Simone is happy to keep loading. £70,000 yesterday, another £50,000 today. More than happy to wait a few months if it means FUM get it right and take this into the £1s.

[j777j] 13/9/2022 08:06

Today’s interim results come on the back of Futura Medical’s success in its FM71 US study. With this hurdle cleared, MED3000 is on track for regulatory approval in the US in early 2023, whilst in Europe, where MED3000 is already approved, Futura’s partner Cooper Consumer Health continues to progress towards a H1 2023 launch. The period-end cash balance of £6.7m leaves the company well-financed significantly beyond initial launches and potential FDA approval. Our forecasts are unchanged and we reiterate a target price of £1.21 pointing to an attractive 160% upside.

[lbo] 13/9/2022 08:03

Seems Co-High have also realised they would lose money trying to launch Med3000 in other regions based on the CE Mark so they have not even tried! LOL

March 2021:

‘Co-High believes the EU (inclusive of the UK) approval of MED3000, expected this year, will facilitate approval in the other countries within the Region’

[keifer derrin] 13/9/2022 08:00

bringing a product to market isn't cheap. I'm also guessing the money producing MED3000 is going add to the cost. They say they now have more than enough product for the launch, so that is going to have an impact on costs.

They have enough money to last for US approval and that doesn't include any milestone payments....

[broomrigg] 13/9/2022 07:58

"Current cash runway extends well beyond expected initial MED3000 launches in the coming months and expected US regulatory approval in Q1 2023."

[lbo] 13/9/2022 07:58

Was it previously 'disclosed' it would take 'years'? Trinity said on 4 March 2021:'The study will likely only need to demonstrate that MED3000's safety and efficacy is replicated in Chinese males, suggesting approval could be achieved within 18 months'

[bob1995] 13/9/2022 07:55

2.5 million spend per period and only 6 million left. Ouch where did it all go

[haveapunt1] 13/9/2022 07:54

Taken from LSE, well summarized:
So, no commercial launch of Eroxon in 2022 (“plans are at an advanced stage for initial launches in first half of 2023”), but since its approved shelf life is 42 months (3 ½ years), “first manufacturing orders have been received from our European partner”, and there will be “at least 3 years shelf-life at point of sale”, initial European launches will be not later than 1 January 2023- 31 March 2023. Really important point - presumably these orders now mean cash royalties have / will begin for Futura, lessening the need for any placing in 2023. The marketing campaign will begin before sales, so I guess in 2022. The search for a US commercial partner has now begun, another positive. No surprise about China: I didn’t see sales there until 2025.

[lbo] 13/9/2022 07:54

LOLChina and Southeast AsiaThe current political environment and restrictive "Zero-Covid" policy in China has resulted in Co-High Investment Management Limited not being able to deliver to-date on the key development and regulatory milestones as set out in the agreement entered into between the companies in March 2021. Futura is exploring options to remedy this situation in line with the contractual terms of the agreement as Southeast Asia including China remains a significant commercial opportunity, although further Phase 3 trials, taking several years, will be required, as previously disclosed.

[broomrigg] 13/9/2022 07:46

Very positive statement and outlook, plenty of cash, happy to stay invested :-)

[lbo] 13/9/2022 07:37

And still no real news on the patent!? LOL

I wonder is the only ‘ novel and inventive nature of the application’ how they said they measured the cooling!!! GSK used a handheld method. But not Futura! ROFLMAO



‘methods of measuring the cooling abaility of a topical composition’




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[lbo] 13/9/2022 07:27

You think it ‘good’ that there is Zero revenues from the Cooper deal yet shareholders were told an ‘ initial upfront payment’ was being paid. Seems Cooper see so little value in Med3000 they paid nothing upfront for it! Yet they admit they paid others to get the deal signed! LOL

‘ The slight increase mainly relates to legal and professional costs associated with concluding MED3000 commercial agreements’

[keifer derrin] 13/9/2022 07:20

good interims....no need to raise any money and like the fact they say MED3000 will launch in the coming months....

[lbo] 13/9/2022 07:14

Zero revenue in the results from the Cooper deal? Yet back in May the RNS said ‘ Futura will receive an initial upfront payment’?

[lbo] 12/9/2022 16:16

So even if Med3000 does get De Novo Medical device registration after the FM71 study. It still cannot substantiate to the FTC or ASA any effect beyond a placebo with any adequately controlled study









In each of the six cases filed, FTC alleged that the companies not only lacked scientific substantiation for their claims regarding the health benefits of their CBD/CBG products, but also falsely represented that their claims were either scientifically proven or had been confirmed by the U.S. government.

Under the proposed orders settling FTC complaints in each of these cases, the companies and their owners are prohibited from making prevention, treatment, or safety claims similar to the ones the companies made about their products about any dietary supplements, foods, and drugs unless they have the human clinical testing to substantiate such claims, and are required to have competent and reliable scientific evidence for any other health-related product claims. Specifically, the testing must be: (1) randomized, double-blind, and placebo-controlled

[haveapunt1] 12/9/2022 16:04

Nice big £70,000 buy now popped in. Loading continues imo

[j777j] 12/9/2022 15:17

The increasingly frantic ramblings of lbo canute show his desperation of being wholly irrelevant.


24/ 7 for the last 2 years and we will soon smash past record previous highs.

[lbo] 12/9/2022 15:12

Really mike? LOLmikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he saysmikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141Company is massively over valued if you go by 'concrete' results !mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the sharesUnfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591"A couple of decent deals and will be back off to the races."Do you have any idea of how long shareholders have been using these wordsmikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713why should it be any different this time when you've still got the same useless lot running the showmikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-lifeAnd where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remunerationI just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

[mikethebike4] 12/9/2022 15:04

LBO

Think you would win an award for obsessive repetition you know

Do you have any pastimes other than this ?

[lbo] 12/9/2022 14:47

All Futura maybe has done is created a new OTC regulatory category for lubricants/arousal gels in men. Allowing Reckitt etc to exploit the equivalence route and sell lubricants/arousal gels as medical device placebo treatments for ED. And report MED3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect beyond a placebo. As Med3000 has not proven any efficacy in any adequately controlled placebo controlled study or even against any standard cooling lubricant/arousal gels already on the market.




‘You are the active ingredient’



Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction